ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern

Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action Binds to all tested variants of concern, likely because it targets a site other than the mutation prone Receptor Binding Domain/ACE2 binding interface Works synergistically with antibodies from other epitope families, making this a potentially promising component for a combination therapy VICTORIA, BRITISH […]